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ABSTRACT
The proportion of ciproﬂoxacin-resistant Gram-
negative bacteria isolated from the blood of
children with cancer (not receiving prophylaxis)
was 10% in a paediatric hospital (Genoa) where
the use of quinolones was highly restricted,
compared with 41% in a department of haema-
tology (Rome) where leukaemic adults, who
received ﬂuoroquinolone prophylaxis, were also
treated (p < 0.0001). Moreover, simultaneous
resistance to ciproﬂoxacin and ceftazidime, ami-
kacin or imipenem–cilastatin was 11% in Genoa
compared with 37% in Rome (p < 0.001). Ciproﬂ-
oxacin resistance was more frequent in children
who shared an environment with adults who
were receiving ciproﬂoxacin prophylaxis.
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Antibacterial prophylaxis with ﬂuoroquinolones
is a common practice in adults with cancer. The
practice decreases the incidence of infections
caused by Gram-negative bacteria, but does not
have a signiﬁcant impact on other clinical param-
eters such as use of empirical antibiotics and
infection-related mortality [1,2]. However, pro-
phylaxis has been associated with the emergence
of resistant Gram-negative bacteria [3–6], which
sometimes also show cross-resistance to b-lactams
and aminoglycosides [7,8], following modiﬁcation
of the microbial ﬂora colonising the patients [4–6].
The use of ﬂuoroquinolones is generally con-
traindicated in children and adolescents aged
< 18 years, as these agents have been shown to
cause cartilage damage in every juvenile animal
model tested at doses similar to those required for
therapeutic purposes [9]. Possible exceptions to
this rule are infections caused by multiresistant
Gram-negative bacteria, exacerbation of cystic
ﬁbrosis, and Gram-negative bacterial infections
in immunocompromised hosts when prolonged
oral therapy is desired [9]. However, in practice,
ﬂuoroquinolones have been used widely for
therapy (targeted or empirical) or prophylaxis of
bacterial infections in neutropenic children with
cancer [10,11], despite the lack of documented
efﬁcacy for the latter population [1,2].
The present study evaluated retrospectively the
proportion of ciproﬂoxacin-resistant Gram-negat-
ive bacteria isolated from blood cultures in two
Italian paediatric cancer units with different
environments during the period 1994–1999. The
ﬁrst centre was at G. Gaslini Children’s Hospital
(Genoa), where widespread use of ﬂuoroquinolo-
nes was restricted, while the second was in the
Department of Cellular Biotechnologies and
Hematology, University ‘La Sapienza’ (Rome),
where leukaemic children and adults are both
treated and ﬂuoroquinolone prophylaxis was
given routinely to adults [12]. Anti-neoplastic
treatment protocols in use at both centres during
the study period were those adopted by the
Italian Association of Pediatric Hematology and
Oncology. In both units, paediatric patients were
admitted to single rooms with procedures of
reverse isolation, and did not receive antibacterial
prophylaxis, and febrile neutropenia was treated
initially with the combination of a third-genera-
tion cephalosporin and an aminoglycoside [13].
Susceptibility of bacterial isolates to ciproﬂoxa-
cin was evaluated by means of the Kirby–Bauer
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method, with results recorded as either suscept-
ible or resistant [14]. Data on resistance to ceftaz-
idime, amikacin and imipenem–cilastatin for
Gram-negative bacteria, and to oxacillin for
Staphylococcus aureus and coagulase-negative
staphylococci, were also collected. In total, 434
bacterial isolates from blood cultures, comprising
260 Gram-negative isolates (54 Pseudomonas aeru-
ginosa, 32 other Pseudomonadaceae, 62 Escherichia
coli, 63 members of the Klebsiella–Enterobacter–
Serratia group, 49 other Gram-negative bacilli) and
174 staphylococci (39 S. aureus and 135 coagulase-
negative staphylococci), were evaluated. Since
sensitivity to ciproﬂoxacin, amikacin, ceftazidime
and imipenem–cilastatin was not always tested for
all isolates, the number of isolates tested was
slightly different for each antibiotic.
Overall, resistance to ciproﬂoxacin was 10% in
Genoa and 41% in Rome (p < 0.0001; Chi-square
test) (Table 1). Variations in the proportions of
ciproﬂoxacin-resistant Gram-negative isolates
were observed throughout the years of the study
(Fig. 1). This phenomenon was evaluated by
inserting the year of observation as a continuous
variable in a logistic regression model [15]. A
slight, but not signiﬁcant, decreasing trend in the
proportion of resistant isolates was present in
both centres (p 0.310 in Genoa; p 0.343 in Rome;
likelihood ratio test), but adjusting for time trend
in a multivariate model did not inﬂuence the
differences observed between the two centres
during the period of the study. The differences in
the overall proportions of Gram-negative bacteria
resistant to the other antibiotics were signiﬁcant
for amikacin (p 0.005) and imipenem–cilastin
(p 0.004), but not for ceftazidime (p 0.6) (Table 1).
The proportions of isolates with resistance to
ciproﬂoxacin and at least one of the other antibi-
otics (ceftazidime, amikacin or imipenem–cilasta-
tin) were 10% (9 ⁄ 86) in Genoa and 37% (43 ⁄ 115)
in Rome (p < 0.001; Chi-square test). Oxacillin
resistance among staphylococci was 37% in
Genoa and 52% in Rome (p 0.069; Chi-square
test), but the proportions of oxacillin-resistant
coagulase-negative staphylococci were very sim-
ilar (49% in Genoa and 56% in Rome). The
proportions of oxacillin-resistant isolates of S. au-
reus were 4% in Genoa and 27% in Rome (p 0.06;
Chi-square test), although this apparent differ-
ence may have been caused by the low number of
isolates (Table 1).
The risk of development of ciproﬂoxacin resist-
ance in cancer centres using ciproﬂoxacin pro-
phylaxis has been associated with changes in the
microbial ﬂora colonising the patients [4–6], and
has sometimes been associated with cross-resist-
ance to antimicrobial agents belonging to other
classes [7,8]. The data in the present study
conﬁrm these observations, but also indicate an
important role for the hospital environment.
Although paediatric cancer patients in both
centres did not receive ciproﬂoxacin prophylaxis,
children treated in Rome had a higher proportion
of bacteraemias caused by ciproﬂoxacin-resistant
bacteria, often associated with resistance to ami-
kacin and imipenem–cilastatin in Gram-negative
bacteria, but not to oxacillin resistance in Gram-
positive bacteria. Since supportive care for chil-
dren was similar in both centres, it is likely that
the differences in the Gram-negative resistance
patterns are attributable to the local environment,
and probably to the widespread use of quinolone
prophylaxis in adults treated in Rome, although
other local factors cannot be excluded completely.
In conclusion, the present study emphasises
the crucial importance of a policy for the use
Fig. 1. Annual proportions of ciproﬂoxacin-resistant
Gram-negative bacteria isolated from blood cultures in
two Italian paediatric centres.
Table 1. Cumulative proportions of bacterial isolates
resistant to different antibiotics from blood cultures in
two Italian paediatric cancer centres
Organism Antibacterial agent
Percentage of resistant
strains
(no. resistant ⁄no. tested)
p valueGenoa Rome
Gram-negative bacteria Ciproﬂoxacin 10 (9 ⁄ 86) 45 (69 ⁄ 155) < 0.0001
Ceftazidime 25 (25 ⁄ 100) 29 (20 ⁄ 69) 0.6
Amikacin 15 (16 ⁄ 105) 31 (46 ⁄ 149) 0.005
Imipenem 7 (7 ⁄ 96) 24 (17 ⁄ 72) 0.004
CNS Oxacillin 49 (36 ⁄ 73) 56 (35 ⁄ 62) 0.69
Staphylococcus aureus Oxacillin 4 (1 ⁄ 28) 27 (3 ⁄ 11) 0.06
CNS, coagulase-negative staphylococci.
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of antimicrobial agents in determining the epi-
demiology of severe infectious complications
caused by antibiotic-resistant pathogens in cancer
hospitals. There is an overall need for more
judicious use of ﬂuoroquinolones, as these
agents may be important for empirical therapy
(both oral and parenteral) of febrile neutropenia,
especially in the presence of b-lactam allergy, or
for the treatment of severe documented infections
caused by multiresistant Gram-negative bacteria.
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ABSTRACT
The possibility of liver involvement in Mycoplas-
ma pneumoniae pneumonia is still controversial.
This study investigated 33 adult patients with
serologically conﬁrmed M. pneumoniae commu-
nity-acquired pneumonia (CAP) (median age
31 years) and 38 patients with bacteraemic Strep-
tococcus pneumoniae CAP (median age 54 years),
all without pre-existing liver disease. Serum
alanine aminotransferase (ALT) levels were ele-
vated in 12 (36.4%) patients with M. pneumoniae
CAP (median 53.5 U ⁄L), and in four (10.5%)
patients with S. pneumoniae CAP (median 61 U ⁄L)
(p 0.025). In most patients with M. pneumoniae
CAP, the elevated ALT levels decreased during
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